Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

TPG Said Near Deal to Purchase Envision Pharmaceutical

July 8 (Bloomberg) -- TPG Capital, the private-equity firm started by David Bonderman and Jim Coulter, is close to an agreement to buy pharmacy-benefits manager Envision Pharmaceutical Holdings Inc., according to a person with direct knowledge of the transaction. Terms weren’t disclosed.

The deal may be announced as early as today, said the person, who asked not to be identified because the agreement isn’t final. Envision, founded in 2001, has annual revenue of more than $3.5 billion.

Pharmacy-benefits managers, known as PBMs, process prescription-drug claims for health-plan customers and negotiate discounts and rebates with drugmakers. The industry is consolidating as PBMs compete to cut costs for their corporate and government clients. Express Scripts Holding Co., the largest U.S. PBM, bought Medco Health Solutions Inc. last year for $29.1 billion, which was followed by SXC Health Solutions Corp.’s $4.4 billion acquisition of Catalyst Health Solutions Inc.

Members of Envision’s management plan to keep a minority stake in the Twinsburg, Ohio-based company, while founders James Mindala, Kevin Nagle and Barry Katz will continue to run the business, the person said.

Owen Blicksilver, a spokesman for TPG at Owen Blicksilver Public Relations Inc., declined to comment, as did Josh Paulen, an Envision spokesman.

TPG, based in Fort Worth, Texas, has announced deals valued at about $5.3 billion in the past 12 months, according to data compiled by Bloomberg. That includes the $1.9 billion buyout of Par Pharmaceutical Cos., a maker of generic drugs.

To contact the reporter on this story: Devin Banerjee in New York at dbanerjee2@bloomberg.net

To contact the editor responsible for this story: Christian Baumgaertel at cbaumgaertel@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.